EDX Medical Group, which develops digital diagnostic products and services enabling delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases, has appointed Erik Jensen as commercial director, UK and Northern Europe.

Jensen has been employed by Becton Dickinson and Abbott laboratories. He is fluent in several European languages and has previously held sales and business development roles based in Denmark, Norway and Sweden. In recent years he was managing director of RefLab, an in vitro diagnostics company specialised in allergy and auto-immune disease testing and pre-clinical contract research based in Denmark and managed the ‘drugs of abuse’ testing service for Abbott Laboratories in the Nordic region.

Jensen said: “I’m exceptionally excited at the opportunity to bring the pipeline of innovative EDX Medical products and services to clients in the UK and Nordic region, supporting our clients with the tools to obtain key patient data, enabling them to pioneer the adoption of personalised medicine for their patients.”

Dr Mike Hudson, chief executive of EDX Medical Group, added: “It gives me great pleasure to welcome Erik to EDX and particularly to be able to work with him to establish commercial operations in the UK and his home territory in the Nordic region. He’s an excellent ambassador for the company and we are confident that he will quickly establish himself as a well-respected partner for our growing network of clients and partners. He will lead the launch of laboratory tests for drug safety, cancer diagnosis and treatment optimisation as well as a new range of point of care tests for the UK pharmacy sector.”

Jensen will be based at the company’s head office in Cambridge.